Sangamo TherapeuticsSGMO
SGMO
About: Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
Employees: 405
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
55% more capital invested
Capital invested by funds: $31.4M [Q2] → $48.5M (+$17.1M) [Q3]
15.27% less ownership
Funds ownership: 42.25% [Q2] → 26.99% (-15.27%) [Q3]
20% less funds holding
Funds holding: 129 [Q2] → 103 (-26) [Q3]
29% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 34
62% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 42
66% less call options, than puts
Call options by funds: $525K | Put options by funds: $1.54M
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$9
264%
upside
Avg. target
$9.50
285%
upside
High target
$10
305%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Patrick Trucchio 30% 1-year accuracy 47 / 158 met price target | 305%upside $10 | Buy Reiterated | 20 Dec 2024 |
Barclays Gena Wang 13% 1-year accuracy 4 / 30 met price target | 264%upside $9 | Overweight Maintained | 14 Nov 2024 |
Financial journalist opinion
Positive
Seeking Alpha
2 days ago
Sangamo: Pipeline Expansion Via Partnership And Internal ST-503 Development
Sangamo Therapeutics, Inc. received IND clearance to initiate a phase 1/2 study for ST-503 targeting idiopathic small fiber neuropathy, a type of chronic neuropathic pain condition. SGMO entered a deal with Astellas, allowing the use of its STAC-BBB capsid for the development of up to 5 neurological disorders; a $20 million upfront payment & $1.3 billion milestone payments. The global Neuropathic Pain market size is projected to grow to $14.05 billion by 2032.
Neutral
PRNewsWire
2 days ago
Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases
- Agreement grants Astellas rights to employ Sangamo's novel proprietary capsid, STAC-BBB, for up to five potential neurological disease targets - - Sangamo to receive a $20 million upfront license fee and is eligible to earn up to $1.3 billion in additional licensed target fees and milestone payments across all five potential disease targets, as well as tiered royalties on potential net sales - TOKYO and RICHMOND, Calif. , Dec. 19, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced they have entered into a license agreement allowing Astellas to leverage Sangamo's novel proprietary neurotropic adeno-associated virus (AAV) capsid, STAC-BBB, which has demonstrated potent blood-brain barrier penetration and neuronal transduction in nonhuman primates.
Neutral
Business Wire
1 month ago
Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain
RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES U.S. FDA CLEARANCE OF IND APPLICATION FOR ST-503 FOR THE TREATMENT OF IDIOPATHIC SMALL FIBER NEUROPATHY.
Neutral
Seeking Alpha
1 month ago
Sangamo Therapeutics, Inc. (SGMO) Q3 2024 Earnings Call Transcript
Sangamo Therapeutics, Inc. (SGMO) Q3 2024 Earnings Call Transcript
Positive
Zacks Investment Research
1 month ago
Sangamo Therapeutics (SGMO) Tops Q3 Earnings and Revenue Estimates
Sangamo Therapeutics (SGMO) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to loss of $0.34 per share a year ago.
Neutral
Business Wire
1 month ago
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results.
Neutral
Business Wire
1 month ago
Sangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast
RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES THIRD QUARTER 2024 CONFERENCE CALL AND WEBCAST.
Positive
Seeking Alpha
1 month ago
Sangamo: Fabry Disease Gene Therapy Moves Forward With Positive FDA Regulatory Development
Positive Type B meeting held with FDA, whereby U.S. agency stated that the phase 1/2 STAAR study using isaralgagene civaparvovec targeting Fabry Disease patients would be enough for Accelerated Approval. The global Fabry Disease treatment market size is expected to be worth $3.34 billion by 2030. Data from the phase 1/2 STARR study, using isaralgagene civaparvovec targeting patients with Fabry Disease, is expected in the first half of 2025.
Neutral
Business Wire
1 month ago
Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025.
Positive
Seeking Alpha
2 months ago
Sangamo Follow-Up: Giro-Vec And STAC-BBB? Check.
Sangamo Therapeutics, Inc.'s stock surged after positive updates on two lead assets, giro-vec and STAC-BBB, with potential for significant milestone payments and partnerships. The upcoming isa-vec deal could be transformative, potentially securing Sangamo's financial stability and pushing its valuation towards $1 billion. Despite recent gains, high volatility and financial risks make SGMO a speculative investment, suitable only for risk-tolerant investors.
Charts implemented using Lightweight Charts™